


PCT

WELTORGANISATION FÜR GEISTIGES EIGENTUM
Internationales Büro



INTERNATIONALE ANMELDUNG VERÖFFENTLICHT NACH DEM VERTRAG ÜBER DIE
INTERNATIONALE ZUSAMMENARBEIT AUF DEM GEBIET DES PATENTWESENS (PCT)

<p>(51) Internationale Patentklassifikation ⁶ : C07C 233/73, 217/58, 271/44, 271/58, 259/06, 271/12, 271/28, 255/13, 235/56, 235/38, 233/75, 59/68, 59/90, A61K 31/165, 31/19</p>	<p>A1</p>	<p>(11) Internationale Veröffentlichungsnummer: WO 95/05358 (43) Internationales Veröffentlichungsdatum: 23. Februar 1995 (23.02.95)</p>
<p>(21) Internationales Aktenzeichen: PCT/EP94/02709 (22) Internationales Anmeldedatum: 13. August 1994 (13.08.94) (30) Prioritätsdaten: P 43 27 365.3 14. August 1993 (14.08.93) DE (71) Anmelder (für alle Bestimmungsstaaten ausser US): BOEHRINGER MANNHEIM GMBH [DE/DE]; D- 68298 Mannheim (DE). (72) Erfinder; und (75) Erfinder/Anmelder (nur für US): WITTE, Ernst-Christian [DE/DE]; Beethovenstrasse 2, D-68165 Mannheim (DE). STEGMEIER, Karlheinz [DE/DE]; Kirchbergstrasse 17, D- 64646 Heppenheim (DE). DOERGE, Liesel [DE/DE]; Am Schelmenbuckel 50, D-68259 Mannheim (DE). (74) Anwälte: WEBER, Manfred usw.; Boehringer Mannheim GmbH, D-68298 Mannheim (DE).</p>		<p>(81) Bestimmungsstaaten: AU, BG, BR, CA, CN, CZ, FI, HU, JP, KR, KZ, NO, NZ, PL, RO, RU, SI, SK, UA, US, europäisches Patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Veröffentlicht <i>Mit internationalem Recherchenbericht. Vor Ablauf der für Änderungen der Ansprüche zugelassenen Frist. Veröffentlichung wird wiederholt falls Änderungen eintreffen.</i></p>
<p>(54) Title: USE OF PHENOLS AND PHENOL DERIVATES AS MEDICAMENTS WITH FIBRINOGEN-REDUCING EFFECT</p>		
<p>(54) Bezeichnung: VERWENDUNG VON PHENOLEN UND PHENOLDERIVATEN ALS ARZNEIMITTEL MIT FIBRINOGENSENK- ENDER WIRKUNG</p>		
<p>(57) Abstract</p> <p>Phenols and phenol derivatives having the general structural formula (I) are used to produce medicaments with fibrinogen-reducing effect. Also disclosed are new phenols and phenol derivatives, a process for producing the same and medicaments containing these compounds. In the formula, R stands for hydrogen or one to three substituents selected independently from each other from the halogen, C₁-C₄-alkyl, C₁-C₄-alkoxy, hydroxy, cyano oder trifluoromethyl series; B stands for a saturated or unsaturated alkylene chain with up to 6 C atoms substituted or not by one or two methyl groups in any desired position. One of the saturated C atoms may be substituted by an oxygen atom or by one of the groups >NH, >C=O oder >CH-OH, and two adjacent saturated C atoms may also be substituted together by a group -CONH- or -NHCO-. X is in a meta- or para-position in relation to B and stands for the following groups: a hydroxy group or a C₁-C₄-alkylurethane or substituted or non-substituted phenylurethane group derived from the hydroxy group; an unbranched or a C₁-C₆-alkyloxy, omega-hydroxy-C₂-C₆-alkyloxy, omega-halogen-C₂-C₆-alkyloxy or omega-cyano-C₁-C₆-alkyloxy group substituted by one or two methyl groups in any desired position; a C₁-C₄-alkyl urethane, a substituted or non-substituted phenyl urethane, phosphoric acid ester, aliphatic carboxylic acid ester grouping or a possibly substituted benzoic acid ester grouping derived from the omega-hydroxy-C₂-C₆-alkoxy group; an aminocarbonyl-C₁-C₆-alkoxy or a N-hydroxy-aminocarbonyl-C₁-C₆-alkoxy group; carboxymethoxy, 1-carboxy-ethoxy, 1-carboxy-propyloxy or 3-carboxy-propyloxy; the residue -O-C-(CH₃)₂-CH₂-O-CO-(CH₂)₂-COOH; the possibly substituted benzyloxy residue.</p> <div style="text-align: center;">  <p>(I)</p> </div>		